TW200813063A - Constrained compounds as CGRP-receptor antagonists - Google Patents

Constrained compounds as CGRP-receptor antagonists Download PDF

Info

Publication number
TW200813063A
TW200813063A TW096115732A TW96115732A TW200813063A TW 200813063 A TW200813063 A TW 200813063A TW 096115732 A TW096115732 A TW 096115732A TW 96115732 A TW96115732 A TW 96115732A TW 200813063 A TW200813063 A TW 200813063A
Authority
TW
Taiwan
Prior art keywords
oxo
mixture
group
mmol
doc
Prior art date
Application number
TW096115732A
Other languages
English (en)
Chinese (zh)
Inventor
Prasad V Chaturvedula
Stephen E Mercer
Hai-Quan Fang
Xiaojun Han
Guanglin Luo
Gene M Dubowchik
Graham S Poindexter
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of TW200813063A publication Critical patent/TW200813063A/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
TW096115732A 2006-05-03 2007-05-03 Constrained compounds as CGRP-receptor antagonists TW200813063A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US79740006P 2006-05-03 2006-05-03
US11/742,626 US7470680B2 (en) 2006-05-03 2007-05-01 Constrained compounds as CGRP-receptor antagonists

Publications (1)

Publication Number Publication Date
TW200813063A true TW200813063A (en) 2008-03-16

Family

ID=38544174

Family Applications (1)

Application Number Title Priority Date Filing Date
TW096115732A TW200813063A (en) 2006-05-03 2007-05-03 Constrained compounds as CGRP-receptor antagonists

Country Status (14)

Country Link
US (1) US7470680B2 (cg-RX-API-DMAC7.html)
EP (1) EP2013214B1 (cg-RX-API-DMAC7.html)
JP (1) JP2009535429A (cg-RX-API-DMAC7.html)
KR (1) KR20090018930A (cg-RX-API-DMAC7.html)
AR (1) AR060845A1 (cg-RX-API-DMAC7.html)
AU (1) AU2007248038A1 (cg-RX-API-DMAC7.html)
BR (1) BRPI0709759A2 (cg-RX-API-DMAC7.html)
CA (1) CA2651033A1 (cg-RX-API-DMAC7.html)
IL (1) IL195027A0 (cg-RX-API-DMAC7.html)
MX (1) MX2008013760A (cg-RX-API-DMAC7.html)
NO (1) NO20084564L (cg-RX-API-DMAC7.html)
PE (1) PE20080232A1 (cg-RX-API-DMAC7.html)
TW (1) TW200813063A (cg-RX-API-DMAC7.html)
WO (1) WO2007131020A2 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7384931B2 (en) * 2004-11-03 2008-06-10 Bristol-Myers Squibb Company Constrained compounds as CGRP-receptor antagonists
CA2672230A1 (en) * 2006-12-20 2008-07-17 Merck & Co., Inc. Benzazepine compounds as cgrp receptor antagonists
JP2011512410A (ja) * 2008-02-19 2011-04-21 メルク・シャープ・エンド・ドーム・コーポレイション イミダゾベンゾアゼピンcgrp受容体アンタゴニスト
US8685969B2 (en) 2010-06-16 2014-04-01 Bristol-Myers Squibb Company Carboline carboxamide compounds useful as kinase inhibitors
US10919914B2 (en) 2016-06-08 2021-02-16 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
GB201707938D0 (en) 2017-05-17 2017-06-28 Univ Sheffield Compounds
WO2024220626A1 (en) * 2023-04-20 2024-10-24 Azkarra Therapeutics, Inc. Small molecule modulators of ogg1

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1606286B1 (en) 2003-03-14 2011-05-11 Merck Sharp & Dohme Corp. Benodiazepine spirohydantoin cgrp receptor antagonists
US7288559B2 (en) 2003-03-14 2007-10-30 Merck + Co, Inc. Carboxamide spirohydantoin CGRP receptor antagonists
WO2004091514A2 (en) 2003-04-15 2004-10-28 Merck & Co., Inc. Cgrp receptor antagonists
JO2355B1 (en) * 2003-04-15 2006-12-12 ميرك شارب اند دوم كوربوريشن Hereditary calcitonin polypeptide receptor antagonists
EP1641781B1 (en) * 2003-06-26 2013-03-06 Merck Sharp & Dohme Corp. Benzodiazepine CGRP receptor antagonists
US7476665B2 (en) * 2003-06-26 2009-01-13 Merck & Co., Inc. Benzodiazepine CGRP receptor antagonists
CN101124217A (zh) 2004-01-29 2008-02-13 默克公司 Cgrp受体拮抗剂
US7390798B2 (en) 2004-09-13 2008-06-24 Merck & Co., Inc. Carboxamide spirolactam CGRP receptor antagonists
US7659264B2 (en) 2004-10-07 2010-02-09 Merck Sharp & Dohme Corp. CGRP receptor antagonists
EP1802637B1 (en) 2004-10-13 2008-10-15 Merck & Co., Inc. Cgrp receptor antagonists
DE602005027870D1 (de) 2004-10-14 2011-06-16 Merck Sharp & Dohme Cgrp-rezeptorantagonisten
US7745427B2 (en) 2004-10-22 2010-06-29 Merck Sharp & Dohme Corp. CGRP receptor antagonists
US7384931B2 (en) * 2004-11-03 2008-06-10 Bristol-Myers Squibb Company Constrained compounds as CGRP-receptor antagonists
US7384930B2 (en) * 2004-11-03 2008-06-10 Bristol-Myers Squibb Company Constrained compounds as CGRP-receptor antagonists
EP1856100B1 (en) 2005-01-18 2010-05-05 Merck Sharp & Dohme Corp. Cgrp receptor antagonists
EP1861399B1 (en) 2005-03-14 2011-12-14 Merck Sharp & Dohme Corp. Cgrp receptor antagonists
CA2615463A1 (en) 2005-07-29 2007-02-08 Merck & Co., Inc. Heterocyclic benzodiazepine cgrp receptor antagonists
CA2672230A1 (en) 2006-12-20 2008-07-17 Merck & Co., Inc. Benzazepine compounds as cgrp receptor antagonists

Also Published As

Publication number Publication date
PE20080232A1 (es) 2008-04-11
WO2007131020A3 (en) 2008-01-17
CA2651033A1 (en) 2007-11-15
US7470680B2 (en) 2008-12-30
KR20090018930A (ko) 2009-02-24
JP2009535429A (ja) 2009-10-01
NO20084564L (no) 2008-12-02
US20070259851A1 (en) 2007-11-08
WO2007131020A2 (en) 2007-11-15
BRPI0709759A2 (pt) 2011-10-25
AR060845A1 (es) 2008-07-16
IL195027A0 (en) 2009-08-03
EP2013214B1 (en) 2015-06-24
MX2008013760A (es) 2008-11-14
EP2013214A2 (en) 2009-01-14
AU2007248038A1 (en) 2007-11-15

Similar Documents

Publication Publication Date Title
US11998545B2 (en) Substituted pyrazolo[1,5-a]pyridine compounds as RET kinase inhibitors
CN110267960B (zh) 作为RET激酶抑制剂的取代的吡唑并[1,5-a]吡嗪化合物
CN111902141A (zh) 用于ikaros降解的羟脑苷脂结合剂
TW201206926A (en) Pyridone and aza-pyridone compounds and methods of use
TW200938542A (en) Compounds and compositions as kinase inhibitors
KR20080073364A (ko) 인돌-3-일-카본일-스피로-피페리딘 유도체
CN102458115B (zh) Iap抑制剂
US7470680B2 (en) Constrained compounds as CGRP-receptor antagonists
CN101495480B (zh) 作为降钙素基因相关肽受体拮抗剂的受限化合物
TW202300150A (zh) 環狀化合物及其使用方法
BR122019019002B1 (pt) Processo de fabricação de compostos de pirazolo[1,5-a]piridina substituídos e kit